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ackground: Human immunodeficiency virus (HIV) infection, it is a global health concern mainly lead to 
acquired immune deficiency syndrome (AIDS). There are numerous limitations of this infection 
particularly in the form of host factors which may limit and interfere HIV-1 replication. The most notable 
host factors which hinder HIV-1 DNA propagation is the apolipoprotein B mRNA-editing enzyme, 
catalytic polypeptide- like 3G (APOBEC3G). Any genetic polymorphism of this substantial host factor may impact 
the host susceptibility pattern to HIV viral infection in different part of the world. The aim of this study to examine 
genetic variants (rs6001417, rs35228531, rs8177832) effecting HIV-1 infection. 
Method: Three variants of APOBEC3G gene polymorphism were genotyped while using RT-PCR method. 
Frequency distribution of these genotypes was evaluated in both the HIV-1 and healthy group. 
Results: The rs6001417 CG (p = 0.03) and rs35228531 CT (p = 0.01) genotypes were found as protective 
elements, while rs35228531 TT (p = 0.02) and rs8177832 AA (p = 0.03) genotypes had shown susceptibility 
against the HIV-1 infection. Our data suggest, rs35228531 CT (p = 0.003) and rs8177832 AA (P = <0.001) 
genotypes have predominant incidences in HIV-1 male population than healthy control. 
Conclusion: We predict rs6001417 CG, rs35228531 CT as protective and rs35228531 TT, rs8177832 AA 
genotypes as a predisposing tool, against the HIV-1 infection in a section of Pakistani population. In addition, 
male gender was found predominantly high in both protective genotype rs35228531 CT ( p = 0.003) and 
predisposing genotype rs8177832 AA ( p = <0.001). The predominant contribution may help the patient to be 
predict about the status of HIV infection, however, extra efforts are required to study larger cohort of patients to 
better elucidate the association.
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Introduction  
HIV-1 infection is a complex and global health dilemma. 
Due to its fatal nature, approximately 37 million 
individuals worldwide are infected with HIV, with each 
passing year 3.1 million new cases emerge [1-3]. Recent 
reports suggest that HIV infection is highly prevalent in 
Sub-Saharan countries [4], however currently in 
Pakistan it is the leading cause of morbidity and mortality 
as it hits approximately 83,468 individuals. Major causes 
of HIV transmission are contaminated blood and sexual 
contacts [5,6]. 
The human immune system provides resistance 
against foreign objects through numerous immune 
strategies, leading to hindrance and elimination of 
foreign objects. In the process, advance and novel 
immune mechanisms are evolved [7-11]. Advancements 
in human genetic studies elucidate that both viral and 
host genetic factors are critically involved in genetic 
susceptibility or protection toward the infectious agents 
[12-14]. Moreover, the individuals with homozygous32 
allelic variant of the CCR5 protein have significant and 
influential outcome, however it does not exhibit complete 
resistance to HIV infection. Interestingly, truncated 
CCR5 is not a known co-receptor for HIV virus, yet it 
provides protection against HIV infection [15,16]. Also, 
the ethnic differences have crucial role in host 
predisposition and/or protection against the disease [17-
19]. Subsequently, relevance of these genetic and ethnic 
differences to a particular disease has started to 
fascinate the researchers worldwide and thus 
manifesting the better understanding of their potential 
role in HIV infection or disease progression. 
Mounting body of evidence suggests that multiple 
host factors affect pathogenesis of HIV-1/AIDS. Likely 
factors include; Apolipoprotein B mRNA editing enzyme 
catalytic polypeptide-like 3G (APOBEC3G), Chemokine 
Receptor 5 (CCR-5), Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), 
Tripartite motif 5a (TRIM5a), Tetherin, and SAM-domain 
HD-domain containing protein (SAMHD1) [5,20-23]. The 
possible defense mechanisms exhibited by these 
elements are antagonized by accessory viral proteins 
[24,25].  
The association of gender with spontaneous 
clearance of HCV has already been reported showing 
link between female gender and rs12979860 CT 
genotype and facilitation in the spontaneous clearance 
of hepatitis C virus potentially [26]. It has been also 
reported that TNFAIP3 rs2230926G may be preliminary 
predictor of systemic lupus erythematous onset in males 
[27]. 
APOBEC3G (antiviral Apolipoprotein B mRNA-
editing enzyme, catalytic polypeptide-like 3G) located on 
chromosome #22q13 [28] is a host intrinsic element, 
which combats HIV-1 infection [29]. Virion infectivity 
factor (vif), a structural part of HIV-1 is able to counteract 
APOBEC3G antiviral activity by targeting it via 
proteasomes [30]. The vif protein derived from different 
subtypes, A, B, CRF01_AE, and CRF02_AG, portray 
comparable anti APOBEC3G activity. On contrary 
subtype C vif protein depicts maximal anti APOBEC3G 
activity [31]. The APOBEC3G protein demonstrates its 
antiviral action by incorporating itself into newly 
synthesized viral particles, in the absence of the vif, 
triggering deamination of cytosine (C) to uracil (U) in 
newly synthesized mutant viral particles. APOBEC3G 
polymorphisms, such as (H186R) rs8177832 are 
associated with pathogenesis in different ethnic groups 
and various HIV-1 subtypes [32,33], however this 
association is not reported in other populations [33]. The 
previous studies did not take concern with circulating 
recombinant forms of HIV-1, nor examine the effect of 
APOBEC3G polymorphisms in Pakistani ethnic groups. 
 The emphasis of present study is to understand and 
evaluate the role of rs6001417, rs35228531, rs8177832 
variants of APOBEC3G polymorphism in HIV-1 infection 
with circulating recombinant in Pakistani population.  
Methods 
This study included a total of 206 individuals involving 
100 HIV-1 seropositive and 106 HIV-1 sero-negative 
individuals. Both groups were obtained in the Imperial 
Diagnostic & Research Center-Imperial College of 
Business Studies Lahore, Pakistan. This study was 
approved by the Institutional Ethical Review Board 
(IERB), Faculty of Health and Allied Sciences (FHAS), 
Imperial College of Business Studies (ICBS), Lahore.  
After obtaining the written consent, whole blood was 
collected from each participant in EDTA container. 
HIV-1 Detection 
Plasma samples obtained by centrifugation at 3500 rpm 
for 5 minutes and were tested for HIV–1 infection, using 
Alere determine HIV-1 or 2 tests (Product code: 
7D2346 CE Chicago, Illinois, United States) as per 
previously reported protocol [34]. 
 
Genotypic determination 
The extraction of genomic DNA was performed from 
whole blood leukocytes, using a non-enzymatic salting-
out method [35]. APO-BEC-3G (rs6001417, rs35228531, 
rs8177832) loci were determined using Fast Real-Time 
PCR (RT-PCR) Systems (Applied Bio-system Step One 
TM). 
The amplified products were run on 2% agarose gel 
along with 50 bp ladder (Fermentas USA) and visualized 
under Wealtec Gel doc system (Fermentas USA). 
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The 184bp DNA fragment of three variants APO-
BEC-3G (rs6001417, rs35228531, rs8177832) was 
amplified by using (SYBR GreenER qPCR super MIX 
Universal kit Invitrogen USA). The primer sequences 
used are given in Table 1. The total volume of PCR 
mixture was 25ul, containing DNA template (1 ul), each 
primer (1 ul) and 10 ul commercial super Mix containing 
Taq-polymerase, MgCl2, dNTPs, Syber green 
fluorescent dye and PCR buffer. Thermocycling was 
performed as; initial denaturation at 95°C for 5 minutes, 
followed by 35 cycles of denaturation at 95°C for 30s, 
annealing at 55°C for 30s and extension at 68°C for 
30s.The final extension was performed at 72°C for 07 
minutes.  
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Statistical Analysis: 
The data was shown as Mean ± SD. The frequencies of 
different genotypes were calculated by direct counting. 
The Variables in the category were compared in different 
groups by using the Chi - square test. All statistical 
analyses were done by using SPSS 22. The independent 
t –test was applied for the demonstration of quantitative 
variation in both the patient and control groups. P-value 
< 0.05 was considered statistically significant.   
Variant’s 
names 
Forward primers Reverse primers 
rs6001417                   CGCGTGCCACCATGAAGATC GTTACAGTCAGCGCCAGACCT 
                                   GTCCGCGTGCCACCATGAAGATG  
rs35228531                 GCGACAATTTGAATCGGT GAGGGATGTCGTGTGACCTT 
                               GCGACAATTTGAATCGGC  
rs8177832                 GAGCCTTGGAATAATCTGCCTA  AGGGAGACCCTCACCTGAGAA 
 TTGAGCCTTGGAATAATCTGCG   
Results 
Table 2:  Association of HIV-1 cases with APO-BEC-3G variants 
genotypes in 100 patients 
Note: This table shows the associations of HV-1 and APO-BEC-3G 
genotypes. Use HIV-1 individuals as the dependent variable, APO-
BEC-3G variant’s genotypes as independent variables. So, 
rs6001417 CG genotype is significantly associated with a higher 
number than GG and CC genotype in both the groups, the 
rs6001417 CG and rs35228531 CT genotypes may help and 
predict the protective role in Healthy individuals. Moreover, it is 
also predicted a predisposing role of and rs35228531 TT and 
rs8177832 AA genotypes against the HIV-1 infection. 
Association between APOBEC3G rs6001417 variant 
and HIV-1 status  
We found that the frequencies of APOBEC3G 
(rs6001417) CC, CG, and GG genotypes were 66.0%, 
27.0%, 7.0% in HIV-1 and 47.2%, 42.5% and 10.4% in 
the control group (Table 2). Individuals reported positive 
for HIV-1 infection had lower frequencies of the 
APOBEC3G (rs6001417) CG, GG genotypes, whereas, 
CC genotype was increased in HIV-1 patients compared 
to controls. Thus, higher prevalence of CG genotype in 
the control group might indicate its possible protective 
role against HIV-1 infection (45 (42.5%) vs 27 (27.0%), p 
= 0.03) (Figure 1). 
 
Figure 1:  Association of protective rs6001417 CG and 
rs35228531 CT genotypes and predisposing rs35228531 TT 
Allele toward the HIV-1 status analysis. 
Note: Genotypes frequency were noted by using Pearson chi 
square test analysis, which also predict the significance level 
(<0.05) of genotypes among the healthy and infected individuals 
and data is shown in percentages. 
Association between APOBEC3G rs35228531 variant 
and HIV-1 status  
APOBEG3G (rs35228531) CC, CT and TT genotypes 
were found to be 52.8%, 41.5%, 5.7% and 58.0%, 
25.0%, 17.0% in control and HIV-1 positive individuals, 
respectively (Table 2). The levels of CC genotype were 
comparable in both control and infected group (p = 0.85), 
however, CT genotype was significantly higher in control 
compared to the infected group (41.5% vs 25.0%, p = 
0.01).  
Furthermore, our data suggest that TT genotype 
frequency was significantly increased in HIV-1 positive 
cases compared to control group (17.0% vs 5.7%, p = 
0.02). (Figure 1).   
Association between APOBEC3G rs8177832 variant 
and HIV-1 status  
APOBEG3G (rs8177832) AA, AG and GG genotypes 
were found as 40.6%, 38.7%. 20.8% and 66.0%, 26.0%, 
08.0% in control and HIV-1 positive individuals, 
respectively (Table 2). The levels of AG and GG 
genotypes were comparable in both control and infected 
groups (p = 0.08 and p = 0.06, respectively), however, 
AA genotype was significantly lower in control compared 
to the infected group (40.6% vs 66.0%, p = 0.03) (Figure 
1).   
APO-BEC-3G 
variants 
Control  
(n = 106) 
Cases  
(n = 100) 
P-value 
rs6001417 Genotypes 
 CC 50 (47.2%) 66 (66.0%) 0.13 
 CG 45 (42.5%) 27 (27.0%) 0.03 (protective) 
 GG 11 (10.4%) 07 (7.0%) 0.34 
rs35228531 
CC 56 (52.8%) 58 (58.0%) 0.85 
CT 44 (41.5%) 25 (25.0%) 0.01 (protective) 
TT 06 (5.7%) 17 (17.0%) 0.02 (risk toward the disease) 
rs8177832                     
AA 43 (40.6%) 66 (66.0%) 0.03 (risk toward the disease) 
AG 41 (38.7%) 26 (26.0%) 0.08 
GG 22 (20.8%) 08 (08.0%) 0.06 
Gender 
Male 67 (63.2%) 54 (76.0%)  
1.4 Female 39 (36.8%) 46 (24.0%) 
Age 39.98±11.38 35.94±9.84 0.1 
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Table 1: Primers of APO-BEC-3G polymorphism genotyping 
Note: This table shows two forward primers and one reverse 
primer for each variant of APO-BEC-3G gene polymorphism 
Generally, in 2018, a total of 129,079 new A total of 206 
individuals were recruited in current study. The 
population investigated consisted of 100 HIV-1 infected 
patients and 106 healthy controls. Age and gender wise 
distribution of the positive cases and healthy groups are 
shown in Table 2. The mean ages were 39.98±11.38 and 
35.94±9.84 in the control and HIV-1 groups respectively. 
Genotype frequencies of all the three APOBEC3G loci 
(rs6001417, rs35228531, rs8177832) for both groups 
are shown (Table 2). 
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Furthermore, we performed correlation analysis in 
between all the genotypes and the three studied variants 
of APOBEC3G in both groups but did not find any 
significant correlation (Table 2). 
Analysis of gender with Protective (rs6001417) CG 
and (rs35228531) CT genotype 
The frequency of protective genotypes of the above-
mentioned variants are shown in Table 3. The frequency 
of rs6001417 CG genotype was slightly higher in the 
males but did not show statically significance (27.5% vs 
45.3%), p = 0.34) (Figure 2). However, rs35228531 CT 
genotype prevalence was significantly higher in male 
group, comparatively 42.1%) vs 21.2%; p = 0.003 (Figure 
2).  
APO-BEC-3G varaiants Male Female P-value 
rs6001417         Genotypes    
CC 75 (62.5%) 41 (47.7%) 0.001 
CG 34 (27.5%) 38 (45.3%) 0.34 
GG 12 (10.0%) 06 (07.0%) 0.15 
rs35228531    
CC 60 (49.6%) 54 (63.5%) 0.57 
CT 51 (42.1%) 18 (21.2%) 0.003 
TT 10 (08.3%) 13 (15.3%) 0.53 
rs8177832                        
AA 74 (61.2%) 35 (41.2%) < 0.001 
AG 35 (28.9%) 32 (37.6%) 0.71 
GG 12 (09.9%) 18 (21.2%) 0.27 
Table 3: Association between APO-BEC-3G polymorphism 
variants and gender 
Note: This table shows the association of dependent variable 
(gender, i.e. male and female) with independent variable APO-
BEC-3G polymorphism genotypes. APO-BEC-3G rs35228531   CT 
may link with gender Male in the protective mechanism, resp. The 
rs8177832 AA genotype also account for raised level of Male 
gender and pertaining to its predisposing role. 
Analysis of gender with Predisposing (rs35228531) 
TT and (rs8177832) AA genotypes 
We found that the distribution of TT genotype was similar 
in male and female groups [male (08.3%) vs female 
(15.3%); p = 0.53] however, rs8177832 AA genotype 
levels were higher in male than female [male (61.2%) vs 
female (41.2%); p = < 0.001] (Figure 2). 
 
Figure 2: Distribution of male and female in protective and 
predisposing APO-BEC-3G variants genotypes.  
Note: Data of genotypes is shown in percentages and chi square 
analysis was done for the prediction of p-value among the male 
and female gender 
Predictive value of protecting and predispose 
features associated with APOBEG3G variants 
genotypes  
As we have mentioned in our earlier results sections that 
the protective features are linked with rs6001417 CG, 
rs35228531 CT, and predisposing with rs35228531 TT, 
rs8177832 AA genotype against HIV-1 infection. In 
addition, we examined the predictive value of these four 
genotypes as well by doing statistical analysis, using 
SPSS version 22.0. Both the rs6001417 CG and 
rs35228531 CT genotypes were appeared as protective 
genotypes, we also explored positive predictive value 
(PPV) which was 42.5% and 41.5%, respectively (Table 
4), which predicts the chance in percentage to reduce 
the risk of being infected with HIV-1 virus. Moreover, the 
rs35228531 TT and rs8177832 AA genotype had shown 
susceptibility towards the onset of HIV-1 infection. The 
PPV calculated was 17.0%, 66.0%, which predicts the 
role of these genotypes regarding the increased risk of 
being infected with HIV-1 virus (Table 4).  
APO-BEC-3G variants PPV NPV Specificity   Sensitivity 
rs6001417   CG 42.5% 27.0% 30.6% 38.1% 
rs35228531 CT 41.5% 25.0% 28.7% 36.9% 
rs35228531 TT 17.0% 5.7% 6.7% 14.5% 
rs8177832 AA 66.0% 37.0 % 55.8% 47.4% 
PPV (positive predictive value), NPV (negative predictive value). 
Table 4: Prediction of APO-BEC-3G polymorphism genotypes in 
HIV-1 infection 
Note: According to this table, rs6001417 CG and rs35228531 CT 
genotype predicting a protective role against HIV-1 disease in 
healthy individuals. Whereas rs35228531 TT and rs8177832 AA 
genotype predicting a predisposing role towards the HIV-1 
individuals. We examined positive and negative predictive value 
of these four genotypes. 
Figure 3: Agarose gel electrophoresis patterns for genetic 
variations of APO-BEC-3G gene polymorphism. 
Note: The RT- PCR analysis shows an electrophoresis pattern of 
three genotypes. (A) Lane M, 184 bp marker; Lane 1, homozygous 
C genotype; Lane 2, heterozygous C/G genotype; Lane 3, 
homozygous G genotype of APO-BEC-3G rs6001417. (B) M lane 
indicates 184 bp marker; Lane 1 shows homozygous C genotype; 
Lane 2, heterozygous C/T genotype and Lane 3 express 
homozygous T genotype of APO-BEC-3G rs35228531. 
Multivariate logistic regression analysis of Male 
gender with protective and predisposing genotypes  
We employed multi-nominal logistic regression to 
interpret the association between APOBEG3G variants 
(protective and predisposing) genotypes and gender in 
the healthy control and HIV-1 group and analyzed the 
following factors: APOBEG3G rs35228531 CT (CC and 
TT were taken as reference genotypes) and gender 
(male vs female). These factors independently and 
significantly contributed to protection against HIV-1 
infection, rs35228531 CT vs CC (reference genotype) 
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(OR, 2.47; CI, 1.28 - 04.77; p = 0.007) and CT vs TT 
(reference genotype) (OR, 3.41; CI, 1.24 – 9.32; P =  
0.017). The CT (protective genotype) (51 (42.1%) vs 18 
(21.2%); (p = < 0.001) was more prevalent in male than 
female group (Table 5) Factor involving in the 
predisposition of the HIV-1 infection in rs35228531 TT 
(predisposed genotype) had a comparable association 
with male and female gender in the disease progression 
(effecting by CC and CT genotypes; OR, 0.37; CI, 0.1 – 
1.01; P = 0.06 and  OR, 0.29; CI, 0.10 – 0.80; p = 0.017, 
respectively) (Table 5). 
Characteristics OR 95% CI P-value 
APO-BEC-3G variants - - - 
Dependent variable Reference 
variable 
- - - 
rs6001417  
Male  Female 1.79 1.00 – 3.23 0.04 
CC GG 1.01 0.35 – 2.95 0.97 
CC CG 2.46 1.32 – 4.59 0.005 
CG GG 0.41 0.13 – 1.23 0.11 
CG CC 0.40 0.21 – 0.75 0.005 
GG CC 0.98 0.33 – 2.85 0.97 
GG CG 2.42 0.81 – 7.25 0.11 
rs35228531  
CC TT 1.37 0.55 – 3.43 0.49 
CC CT 0.40 0.20 – 0.77 0.007 
CT  TT 3.41 1.24 – 9.32 0.017 
CT CC 2.47 1.28 – 4.77 0.007 
TT CC 0.37 0.1 – 1.01 0.06 
TT CT 0.29 0.10 – 0.80 0.017 
rs8177832  
AA GG 4.17 1.72 – 10.11 0.002 
AA AG 2.30 1.19 – 4.44 0.013 
AG GG 1.81 0.74 – 4.41 0.19 
AG AA 0.43 0.22 – 0.83 0.013 
GG AG 0.55 0.22 – 1.34 0.19 
GG AA 0.24 0.09 – 0.58 0.002 
CI, Confidence interval, OR, Odd ratio, APO-BEC-3G 
Table 5: Multi-nominal logistic regression analysis of Male gender 
to the protective and predisposing genotypes of APO-BEC-3G   
variants   
Note: This table shows the MLM (multi logistic model) analysis, 
which predicted the male gender contribution, the rs35228531 CT 
a protective genotype strongly favors by Male than Female gender 
after comparing with CC  and TT genotypes, whereas rs6001417 
CG a protective genotype show comparable association against GG 
and CC genotypes with both male and female genders. The 
rs35228531 TT a predisposing genotype also equally contributed 
by both the gender than CT and TT whereas, rs8177832 AA 
genotype favoring by Male as well after compared with GG and AA 
genotypes. 
Moreover, our analysis also revealed the significant 
effect of male gender on rs8177832 AA a predisposed 
genotype towards HIV-1 infection (effecting by AG and 
GG genotypes; OR, 4.17; CI, 1.72 – 10.11; p = 0.002 and  
OR, 2.30; CI, 1.19 – 4.44; p = 0.013, respectively) (Table 
5). HIV-1 studied individuals with rs6001417 CG 
(protective genotype) almost didn’t show any distinct 
contribution for both male and female ((effecting by GG 
and CC genotypes; OR, 0.41; CI, 0.13 – 1.23; P = 0.11 
and  OR, 0.40; CI, 0.21 – 0.75; P = 0.005, respectively) 
(Table 5). 
Discussion  
Continual exposure to HIV infection may not certainly 
result in AIDS occurrence [36]. Multiple genetic and 
immune factors help in HIV acquirement, pathogenesis 
and AIDS progression at various stages of HIV life-cycle. 
So, HIV infection activates multiple intrinsic host factors 
that confer resistance to HIV pathogenesis. One of the 
important factors that substantiate intrinsic inhibition to 
HIV infection is APOBEC3G genetic host factor [24,37]. 
APOBEC3G single nucleotide polymorphisms (SNPs) 
are of particular importance. Its numerous SNPs have 
been studied in American [38] and European [39] 
populations in relation to its influence on AIDS 
development and progression. To our knowledge, the 
role of APOBEC3G in relation to HIV-1 infection has not 
been reported before in Pakistani population. Therefore, 
in current study we have investigated the frequency 
distribution of  the three variants of APOBEC3G gene 
polymorphism in residents of Pakistan [40] and 
association of these variants with HIV-1 pathogenesis.  
Our results suggest that the most common genotype 
prevalence was CC in APOBEC3G variants (rs6001417, 
rs35228531),and AA in rs8177832 followed by CG, GG 
and CC, CT and AG,GG respectively, in both HIV-1 
infected and uninfected populations. Briefly, in 
rs6001417 homozygous genotypes CC (p = 0.13) and 
GG (p = 0.34) distribution was quite comparable in both 
groups. However, heterozygous genotype CG incidence 
is significantly elevated in control than HIV-1 positive 
group (p = 0.03). We assume that higher incidence in 
control group exhibits the possible protective role against 
HIV-1 infection [41]. 
Similarly, in rs35228531 variant CC genotype 
occurrence was comparable in both groups (p = 0.85). 
On other hand, TT genotype distribution is more 
prevalent in infected group (p = 0.02). Thus, indicates a 
potential role in susceptibility related to HIV infection. 
Yet, CT a heterozygous genotype is distributed more 
frequently in control group (p = 0.01). This demonstrates 
the possible protective feature of CT genotype against 
HIV-1 pathogenesis. Moreover, AA genotype of 
rs8177832 variant has been shown a significant 
contribution towards the HIV infected individuals in the 
region (P = <0.001), while AG and GG attained a 
comparable participation in both the infected and healthy 
individuals. In brief, AA genotype has assumed the 
highest in HIV-1 group may depict the possible 
predisposed role towards HIV-1 infection. 
In a previous study, carried out in Burkina Faso-West 
Africa, the role of the aforementioned variants has been 
substantiated in regard with providing protection against 
HIV-1 infection and rapid disease progression (up to 2 to 
5 folds) [42]. Moreover, rs8177832 (H186R) mutation 
association with high HIV-1 loads and decreased CD4+ 
count in south African females was also shown[38]. 
However, another group could not establish the 
association between APOBEC3G variants (including 
rs6001417 and rs8177832 but not rs35228531) and a 
disease progression phenotype in white French HIV-1 
seropositive individuals [43,44]. Contradictory paradigm 
of APOBEC3G role against HIV-1 infection may be 
attributed to either prevalence of non-identical virus 
strains in different regions or genetic variations in 
different populations and ethnic group. A study of 3,073 
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subjects from six different cohorts demonstrated that the 
distribution of this genetic variation in African Americans 
was 37% but rare in European American (<3%) and in 
Europeans (5%) [7]. Moreover, the SNPs of APOBEC3G 
interacting proteins such as Vif and CUL5 may also 
influence the disease progression [45]. 
We have shown that, the effect of APOBEC3G 
variants is gender-depended i.e, rs35228531 CT 
genotype frequency is higher in male than female (p < 
0.001) (Table 3). Apparently, the profound incidence of 
rs35228531 CT genotype supports the males in term of 
protection against the HIV-1 infection. However, our 
results further indicate that in variant rs8177832 
genotype AA incidence is also higher in male then female 
(p < 0.001) (Table 3). The elevated incidence of variant 
rs8177832 genotype AA makes male group more 
vulnerable to the pathogenesis of HIV-1 infection. To the 
best of our knowledge, there is no prior study or report 
showing the association between the gender and 
APOBEC3G gene polymorphism in HIV-1 infection.Role 
of SNP genotypes and their association with male 
gender has been reported previously in systemic lupus 
erythematous (SLE) patients [27]. Moreover, we have 
recently reported that both genders favor IL28B 
rs12979860 CT genotype (OR: 4.80; CI: 2.22–10.35; p = 
0.0005) and (OR: 3.47; CI: 1.63–7.43; p = 0.001) for male 
and female, respectively, in spontaneous clearance of 
HCV infection [26,27]. 
Our results showed that, APOBEC3G rs6001417 CG 
and rs35228531 CT genotypes provide protection with 
42.5% and 41.5% positive predictive value (PPV) 
respectively, for HIV-1 infection while rs35228531 TT 
genotype with predictive value of 17.0% had shown a 
predispose role against the HIV-1 studied population. In 
a previous study, using HCV patients, showed the 
predictive role of SNP rs12979860 genotypes of IL28B in 
HCV infection   [46,47]. Themulti logistic model (MLM) 
analysis, which predicted the predominant male group 
contribution in elevating protection against HIV-1 
infection and aggravating the onset of the infection. The 
rs35228531 genotype CT promotes the protective 
probability 3 and 2-fold by male than female group.  In a 
previous study carried out on Burkina Faso population 
none of the rs35228531 genotypes (CT, CC, TT) 
demonstrated the role in protecting against HIV-1. Our 
findings showed CC genotype had 3-times the risk of 
being infected. Concurrently, our multinomial logistic 
regression analysis substantiates that the rs8177832 
genotype AA carriers pose 4 and 2-fold predisposing 
toward the infection OR=4.17 [95% CI: 1.72-10.11, 
p=0.002] and OR=2.30 [95%CI: 1.19-4.44, p=0.013] (vs 
genotypes GG and AG, respectively) by male than 
female gender. 
In current study, we have reported the possible 
biological role of APOBEC3G gene variants 
(rs35228531, rs35228531 and rs6001417) in promoting 
and/or repressing the HIV-1 infection between male and 
female in Pakistani population. As far as we know, this is 
the first study examining the role of APOBEC3G gene 
variants on HIV-1 infection in a Pakistani population in 
both gender, where we found male a possible 
predominant . In short, male gender was found 
predominatly high in both protective gentotype 
rs35228531 CT (p = 0.003) and predisposing genotype 
rs8177832 AA (p = <0.001). This predomiant contribution 
may help the patient to be predict about the status of HIV 
infection. However, the major limitation, is that the 
current study was carried out on a limited sample size. 
The findings, based on such a sample size / population 
fraction are not enough to infer to the whole population. 
In order to have a better understanding of the above-
mentioned association further investigations are needed 
for a substantial part of the population.  
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